Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift.

The study was to explore the rational use of danofloxacin against Mycoplasma gallisepticum ( MG ) based on its clinical breakpoint (CBP) and the effect on lung microbiota. The CBP was established according to epidemiological cutoff value (ECV/CO WT ), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (CO PD ) and clinical cutoff value (CO CL ). The ECV was determined by the micro-broth dilution method and analyzed by ECOFFinder software. The CO PD was determined according to PK-PD modeling of danofloxacin in infected lung tissue with Monte Carlo analysis. The CO CL was performed based on the relationship between the minimum inhibitory concentration (MIC) and the possibility of cure (POC) from clinical trials. The CBP in infected lung tissue was 1 μg/mL according to CLSI M37-A3 decision tree. The 16S ribosomal RNA (rRNA) sequencing results showed that the lung microbiota, especially the phyla Fi rmicutes and Proteobacteria had changed significantly along with the process of cure regimen (the 24 h dosing interval of 16.60 mg/kg b.w for three consecutive days). Our study suggested that the rational use of danofloxacin for the treatment of MG infections should consider the MIC and effect of antibiotics on the respiratory microbiota.